These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 30808819)

  • 1. Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition.
    Katsuno Y; Meyer DS; Zhang Z; Shokat KM; Akhurst RJ; Miyazono K; Derynck R
    Sci Signal; 2019 Feb; 12(570):. PubMed ID: 30808819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.
    Zhou H; Yu C; Kong L; Xu X; Yan J; Li Y; An T; Gong L; Gong Y; Zhu H; Zhang H; Yang X; Li Y
    Oncogene; 2019 May; 38(18):3371-3386. PubMed ID: 30635656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.
    Park SY; Kim MJ; Park SA; Kim JS; Min KN; Kim DK; Lim W; Nam JS; Sheen YY
    Oncotarget; 2015 Nov; 6(35):37526-43. PubMed ID: 26462028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-β-induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma.
    Malfettone A; Soukupova J; Bertran E; Crosas-Molist E; Lastra R; Fernando J; Koudelkova P; Rani B; Fabra Á; Serrano T; Ramos E; Mikulits W; Giannelli G; Fabregat I
    Cancer Lett; 2017 Apr; 392():39-50. PubMed ID: 28161507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure Identification of ViceninII Extracted from
    Luo Y; Ren Z; Du B; Xing S; Huang S; Li Y; Lei Z; Li D; Chen H; Huang Y; Wei G
    Molecules; 2019 Jan; 24(1):. PubMed ID: 30609689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stem cells induce epithelial mesenchymal transition in melanoma by paracrine secretion of transforming growth factor-β.
    Lv C; Dai H; Sun M; Zhao H; Wu K; Zhu J; Wang Y; Cao X; Xia Z; Xue C
    Melanoma Res; 2017 Apr; 27(2):74-84. PubMed ID: 28079609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian Target of Rapamycin (mTOR) Regulates Transforming Growth Factor-β1 (TGF-β1)-Induced Epithelial-Mesenchymal Transition via Decreased Pyruvate Kinase M2 (PKM2) Expression in Cervical Cancer Cells.
    Cheng KY; Hao M
    Med Sci Monit; 2017 Apr; 23():2017-2028. PubMed ID: 28446743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
    Du B; Shim JS
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.
    Wu K; Ding J; Chen C; Sun W; Ning BF; Wen W; Huang L; Han T; Yang W; Wang C; Li Z; Wu MC; Feng GS; Xie WF; Wang HY
    Hepatology; 2012 Dec; 56(6):2255-67. PubMed ID: 22898879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics.
    Dang H; Ding W; Emerson D; Rountree CB
    BMC Cancer; 2011 Sep; 11():396. PubMed ID: 21929801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
    Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.
    Wang TY; Peng CY; Lee SS; Chou MY; Yu CC; Chang YC
    Oncotarget; 2016 Dec; 7(51):84072-84081. PubMed ID: 27557511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
    Brown WS; Akhand SS; Wendt MK
    Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Disintegrin and Metalloprotease ADAM12 Is Associated with TGF-β-Induced Epithelial to Mesenchymal Transition.
    Ruff M; Leyme A; Le Cann F; Bonnier D; Le Seyec J; Chesnel F; Fattet L; Rimokh R; Baffet G; Théret N
    PLoS One; 2015; 10(9):e0139179. PubMed ID: 26407179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic Plasticity Determines Cancer Stem Cell Therapeutic Resistance in Oral Squamous Cell Carcinoma.
    Biddle A; Gammon L; Liang X; Costea DE; Mackenzie IC
    EBioMedicine; 2016 Feb; 4():138-45. PubMed ID: 26981578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer.
    Islam SS; Mokhtari RB; Noman AS; Uddin M; Rahman MZ; Azadi MA; Zlotta A; van der Kwast T; Yeger H; Farhat WA
    Mol Carcinog; 2016 May; 55(5):537-51. PubMed ID: 25728352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin enhances cisplatin sensitivity of resistant non-small cell lung carcinoma stem-like cells by targeting mTOR-Akt axis to repress migration.
    Khan P; Bhattacharya A; Sengupta D; Banerjee S; Adhikary A; Das T
    Sci Rep; 2019 Nov; 9(1):16913. PubMed ID: 31729456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PGE
    Lin MC; Chen SY; He PL; Herschman H; Li HJ
    Int J Cancer; 2018 Sep; 143(6):1440-1455. PubMed ID: 29658109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.